5-HT2C受体阻断逆转SSRI相关基底节功能障碍并增强疗效
该研究在小鼠中揭示SSRI通过作用于黑质网状部(SNr)的5-HT2C受体抑制黑质致密部(SNc)多巴胺能神经元,导致运动功能障碍。全身或SNr局部5-HT2C受体拮抗可逆转SSRI诱导的运动缺陷及SNr过度活跃和SNc活动不足,并增强SSRI的抗抑郁和抗焦虑效果。
要点
- SSRI通过SNr的5-HT2C受体抑制SNc多巴胺能神经元导致运动障碍。
- 5-HT2C受体拮抗可逆转SSRI诱导的运动缺陷及神经活动异常。
- 5-HT2C受体拮抗增强SSRI的抗抑郁和抗焦虑疗效。
核心结论
- 5-HT2C受体在SSRI对运动功能和情感行为的影响中作用相反,拮抗该受体可减少运动副作用并增强疗效。
研究设计与样本
- 小鼠实验研究,采用全身或SNr局部5-HT2C受体拮抗、光遗传学抑制或激活SNc多巴胺能神经元等方法。
主要发现
- SSRI诱导SNr过度活跃和SNc活动不足,可被全身5-HT2C受体拮抗逆转。
- 光遗传学抑制SNc多巴胺能神经元模拟慢性SSRI治疗的运动缺陷。
- SNr局部5-HT2C受体拮抗或光遗传学激活SNc多巴胺能神经元逆转SSRI诱导的运动缺陷。
- 5-HT2C受体拮抗增强SSRI的抗抑郁和抗焦虑效果。
临床怎么用
- 5-HT2C受体拮抗可能用于减少SSRI相关运动副作用并增强抗抑郁抗焦虑疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Serotonin (5-HT) selective reuptake inhibitors (SSRIs) are widely used in the treatment of depression and anxiety disorders, but responsiveness is uncertain and side effects often lead to discontinuation. Side effect profiles suggest that SSRIs reduce dopaminergic (DAergic) activity, but specific mechanistic insight is missing. Here we show in mice that SSRIs impair motor function by acting on 5-HT2C receptors in the substantia nigra pars reticulata (SNr), which in turn inhibits nigra pars compacta (SNc) DAergic neurons. SSRI-induced motor deficits can be reversed by systemic or SNr-localized 5-HT2C receptor antagonism. SSRIs induce SNr hyperactivity and SNc hypoactivity that can also be reversed by systemic 5-HT2C receptor antagonism. Optogenetic inhibition of SNc DAergic neurons mimics the motor deficits due to chronic SSRI treatment, whereas local SNr 5-HT2C receptor antagonism or optogenetic activation of SNc DAergic neurons reverse SSRI-induced motor deficits. Lastly, we find that 5-HT2C receptor antagonism potentiates the antidepressant and anxiolytic effects of SSRIs. Together our findings demonstrate opposing roles for 5-HT2C receptors in the effects of SSRIs on motor function and affective behavior, highlighting the potential benefits of 5-HT2C receptor antagonists for both reduction of motor side effects of SSRIs and augmentation of therapeutic antidepressant and anxiolytic effects.
引用
- Demireva EY, Suri D, Morelli E, et al. 5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy. Mol Psychiatry. 2018. PMID: 30120415. doi:10.1038/s41380-018-0227-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。